CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee is scheduled to discuss the Company’s Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) on February 4, 2009. An advisory committee is a group of experts that provides the FDA with advice and is convened by the FDA as part of its review of a novel therapy.
